dm+d

Unassigned

New Medicines

Disability following acute stroke

Information

New molecular entity
ReNeuron
ReNeuron

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Neural stem cell therapy. This therapy contains CTX stem cells which are based on cells from the cortex region of the brain.
Approximately 150,000 people suffer a stroke in the UK each year. Around one half of survivors are left with permanent disabilities as a result of the damage caused to brain tissue arising from the stroke. Beyond the acute phase, there are only preventative or rehabilitation measures [1].
Disability following acute stroke
Stereotactic
Parenteral